Since 1980, a total of 26 clinical trials have been conducted on Helixor mistletoe products. Most trials sought to determine whether mistletoe cancer treatment can prolong survival and/or improve quality of life.
The spectrum of malignant diseases is very broad. Mistletoe therapy has been studied in patients with:
- Various stages of breast cancer
- Lung cancer
- Various stages of colon cancer
- Chronic myeloid leukemia
- Ovarian cancer
- Pleural carcinosis (effusion in the pleural cavity compressing the lung)
- Malignant lymphoma
- Malignant melanoma
- Pancreatic cancer
Of these 26 trials, we would like to highlight four:
- Piao et al. (2004) studied 224 patients with breast, ovarian, and non-small cell lung cancer. This is one of the most important studies on the use of mistletoe therapy, because it meets the criteria of modern clinical trial and the standards of evidence-based medicine. It demonstrated that mistletoe cancer treatment can significantly improve quality of life and reduce the side effects of chemotherapy.
- Auerbach et al. (2005) studied 20 patients with breast cancer. This relatively small study clearly showed that mistletoe therapy can reduce side effects of chemotherapy, particularly unfavorable effects on key immune cells. The need for other drugs decreased.
- Tröger et al. (2014) studied 65 patients with breast cancer in stages I - III. Using high-quality methodology, this clinical trial proved that mistletoe therapy can significantly improve quality of life during chemotherapy, and possibly reduce chemotherapy’s adverse effects on the white blood cell count.
- Mansky et al. (2013) studied patients with advanced solid tumors of the breast, colon, pancreas, and lung. This study demonstrated that mistletoe does not inhibit the effect of chemotherapy and can even boost its efficacy – because the cytotoxic drug (in this study: gemcitabine) can be given in higher dosages due to a better tolerability.